Trial and error in clinical studies: Lessons from ATAMS

The Lancet Neurology

Volumn 13, Issue 4, 2014, Pages 340-341

  Lühder, Fred ^a,b   Gold, Ralf ^c  

^a Gemeinnutzige Hertie Stiftung   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATACICEPT; IMMUNOGLOBULIN; OCRELIZUMAB; PLACEBO; RITUXIMAB;

B LYMPHOCYTE; CELL DIFFERENTIATION; DISEASE ACTIVITY; HUMAN; MEMORY CELL; MULTIPLE SCLEROSIS; NONHUMAN; NOTE; PRIORITY JOURNAL;

FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECOMBINANT FUSION PROTEINS;

EID: 84896081670     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70050-X     Document Type: Note

References (14)

1. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688.
2. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011, 378:1779-1787.
3. Kappos L, Hartung H-P, Freedman MS, et al. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol 2014, for the ATAMS Study Group, published online March 6. http://dx.doi.org/10.1016/S1474-4422(14)70028-6.
4. Genovese MC, Kinnman N, de La Bourdonnaye G, Pena Rossi C, Tak PP Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum 2011, 63:1793-1803.
5. Dall'Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007, 56:4142-4150.
6. Mackay F, Browning JL BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002, 2:465-475.
7. Krumbholz M, Faber H, Steinmeyer F, et al. Interferon-β increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 2008, 131:1455-1463.
8. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004, 14:164-174.
9. Berer K, Wekerle H, Krishnamoorthy G B cells in spontaneous autoimmune diseases of the central nervous system. Mol Immunol 2011, 48:1332-1337.
10. + T cell immunity. Nat Rev Immunol 2010, 10:236-247.
11. Yang M, Sun L, Wang S, et al. Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells. J Immunol 2010, 184:3321-3325.
12. Harp CT, Ireland S, Davis LS, et al. Memory B cells from a subset of treatment naïve relapsing remitting multiple sclerosis patients elicit CD4+ T cell proliferation and IFN-γ production in response to MBP and MOG. Eur J Immunol 2010, 40:2942-2956.
13. Pillai S, Mattoo H, Cariappa A B cells and autoimmunity. Curr Opin Immunol 2011, 23:721-731.
14. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999, 53:457-465. The Lenercept Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis GroupThe University of British Columbia MS/MRI Analysis Group.